Therapeutic Area

Cardiovascular

Therapeutic area intelligence for Cardiovascular with 16 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 16
Catalysts: 0
Companies: 9

Companies

Sciegen Pharmaceuticals →

Strides Pharma →

Assets

Hydrochlorothiazide →

Recent signals(16)

StrategyJune 21, 2026

FDA Grants Approval for Propranolol Hydrochloride ANDA219165

The FDA has granted approval for the ANDA219165 application for Propranolol Hydrochloride submitted by PAI Holdings.

RegulatoryJune 21, 2026

Cipla's NDA for Argatroban in Sodium Chloride Receives AP Status from FDA

Cipla's supplemental NDA for Argatroban in Sodium Chloride has been granted an Approval Pending (AP) status by the FDA.

ClinicalJune 21, 2026

Study on Low-Dose Antihypertensive Therapy in Prehypertensive Chinese Population

The study evaluates low-dose antihypertensive therapy's impact on new-onset hypertension and diabetes in high-normal blood pressure individuals.

RegulatoryJune 21, 2026

FDA Accepts Supplemental NDA for Argatroban in Sodium Chloride

The FDA has accepted a supplemental NDA for Argatroban in Sodium Chloride submitted by Eugia Pharma.

RegulatoryJune 21, 2026

FDA Grants AP Status for Losartan Potassium ANDA090382 by Strides Pharma

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Losartan Potassium submitted by Strides Pharma.

StrategyJune 21, 2026

Lupin's ANDA078232 for Losartan Potassium Receives AP Status from FDA

Lupin Ltd. has received an Abbreviated New Drug Application (ANDA) approval status for Losartan Potassium.

StrategyJune 21, 2026

Sandoz receives AP status for Irbesartan and Hydrochlorothiazide ANDA

Sandoz's ANDA077446 for Irbesartan and Hydrochlorothiazide has received an Abbreviated Approval (AP) status.

StrategyJune 20, 2026

Ezetimibe-atorvastatin SPC approved in China; economic value assessment needed

The single-pill combination of ezetimibe and atorvastatin was approved in China in 2023 and added to the NRDL in 2024.

StrategyJune 19, 2026

FDA Approves ANDA216272 for Norepinephrine Bitartrate by Nephron

The FDA has approved ANDA216272, a generic formulation of Norepinephrine Bitartrate, submitted by Nephron.

RegulatoryJune 19, 2026

Abiomed and Oscor Warn of Catheter Introducer Leakage Risk

Abiomed and Oscor reported a potential leakage issue in their introducer sheaths that may lead to increased access-site bleeding.

CompetitiveJune 16, 2026

Merck Publishes Method for Scalable Synthesis of Oral PCSK9 Inhibitor Enlicitide Decanoate

Merck has published a method for the large-scale synthesis of enlicitide decanoate, an investigational oral PCSK9 inhibitor.

ClinicalJune 16, 2026

Lilly's VERVE-102 Shows Significant LDL-C Reduction in Phase 1b Trial

VERVE-102 reduced PCSK9 levels by up to 88% and LDL-C by up to 62% in Phase 1b trial, with effects lasting up to 18 months.

StrategyJune 9, 2026

FDA Grants Approval for Olmesartan Medoxomil and Hydrochlorothiazide ANDA206371

The FDA has granted approval for ANDA206371, a combination of Olmesartan Medoxomil and Hydrochlorothiazide, submitted by Micro Labs.

RegulatoryJune 9, 2026

FDA Grants AP Status for Diltiazem Hydrochloride ANDA216327

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Diltiazem Hydrochloride submitted by Sciegen Pharmaceuticals.

RegulatoryJune 7, 2026

FDA Approval Status Update for Losartan Potassium by Micro Labs

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Losartan Potassium submitted by Micro Labs.

RegulatoryJune 6, 2026

FDA Grants Approval for Phenylephrine Hydrochloride by Baxter Healthcare

The FDA has granted approval for ANDA217032, a new application for Phenylephrine Hydrochloride submitted by Baxter Healthcare.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.